Topiramate (All indications)

Very preterm (28 to 32 weeks)

id	Study   Auto Coste (Topiramate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2020Coste (Topiramate) (Controls unexposed, NOS) (Mixed indications), 2020	Lib. in paper	Exposition period  Auto during pregnancy (anytime or not specified)1st trimester2nd trimester3rd trimester2nd and/or 3rd trimesterthroughout pregnancyearly pregnancydays before deliverylate pregnancypreconception-onlypericonceptionalpreconceptional for kinetic reasonat least 1st trimester3 months (or more) before pregnancy or during pregnancy1st and 2nd trimester3 months or more before pregnancy or1st trimester	Study type  All studies Case control excluded Only case control	Control type    Auto unexposed (general population or NOS)unexposed, sickunexposed, disease freeexposed to other treatment, sicknot specifiedwhatever (meta-analysis)	Tags	OR 95%CI	x1/n1 x0/n0	no cases	no exposed	ROB	Ref.
S10103 R36811	Coste (Topiramate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2020	Gestational age at birth (< 32 WA)	during pregnancy (anytime or not specified)	retrospective cohort (claims database)	exposed to other treatment, sick excluded	Adjustment: No	3.93 [1.52;10.20] C excluded (control group)	7/477   11/2,916	18	477		ref
S8613 R28729	Coste (Topiramate) (Controls unexposed, NOS) (Mixed indications), 2020	Gestational age at birth (27–31 WA)	during pregnancy (anytime or not specified)	retrospective cohort (claims database)	unexposed (general population or NOS)	Adjustment: No	2.53 [1.13;5.65] C	6/477   8,584/1,710,441	8,590	477		ref
					Total	1 studies	2.53 [1.13;5.65]		8,590	477
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

Sensitivity analysis

Publication bias and p-hacking diagnosis

Sub-groups analysis using all included studies

excluded 10103